ÌÇÐÄvlog

[Skip to Navigation]
Sign In

October 2024 - April 2015

Decade

Year

Issue

June 2022, Vol 8, No. 6, Pages 808-951

Original Investigation

Association of Pathogenic Variants in Hereditary Cancer Genes With Multiple Diseases

Abstract Full Text
free access
JAMA Oncol. 2022;8(6):835-844. doi:10.1001/jamaoncol.2022.0373

This phenome-wide association study uses phenotypic data derived from health records in 3 cohorts to investigate a broad range of phenotypes associated with hereditary cancer genes.

Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: The ORATOR2 Phase 2 Randomized Clinical Trial

Abstract Full Text
free access has audio
JAMA Oncol. 2022;8(6):845-851. doi:10.1001/jamaoncol.2022.0615

This randomized clinical trial examines a primary radiotherapy approach vs a primary transoral surgical approach in treatment deescalation for HPV-related oropharyngeal squamous cell carcinoma.

Quality-of-Life Outcomes and Toxic Effects Among Patients With Cancers of the Uterus Treated With Stereotactic Pelvic Adjuvant Radiation Therapy: The SPARTACUS Phase 1/2 Nonrandomized Controlled Trial

Abstract Full Text
free access
JAMA Oncol. 2022;8(6):853-861. doi:10.1001/jamaoncol.2022.0362

This multicenter phase 1/2 nonrandomized controlled trial describes the physician-reported acute genitourinary and gastrointestinal toxic effects and patient-reported quality-of-life changes associated with undergoing stereotactic hypofractionated adjuvant radiation therapy of the pelvis for treatment of uterine cancer.

Association of Medicaid Expansion With Mortality Disparity by Race and Ethnicity Among Patients With De Novo Stage IV Breast Cancer

Abstract Full Text
free access
JAMA Oncol. 2022;8(6):863-870. doi:10.1001/jamaoncol.2022.0159

This cross-sectional study examines the association between Medicaid expansion and mortality disparities among racial and ethnic minority patients with de novo stage IV breast cancer.

Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants

Abstract Full Text
open access
JAMA Oncol. 2022;8(6):871-878. doi:10.1001/jamaoncol.2022.0476

This case-control study examines the association of BRCA1 and BRCA2 pathogenic variants with additional cancer types and their clinical characteristics in 100 914 Japanese individuals across 14 cancer types.

Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class

Abstract Full Text
free access
JAMA Oncol. 2022;8(6):879-886. doi:10.1001/jamaoncol.2022.0864

This cohort study assesses whether cancer drug trials that show improvement in overall survival or progression-free survival also improve global quality of life in patients with cancer and how unchanged or detrimental quality-of-life outcomes are reported in trial publications.

Identifying Patients Whose Symptoms Are Underrecognized During Treatment With Breast Radiotherapy

Abstract Full Text
free access
JAMA Oncol. 2022;8(6):887-894. doi:10.1001/jamaoncol.2022.0114

This cohort study examines patient-reported outcomes of patients with breast cancer who received radiotherapy and their physicians’ Common Toxicity Criteria for Adverse Events assessments to assess underrecognition of symptoms.

Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype

Abstract Full Text
free access
JAMA Oncol. 2022;8(6):895-903. doi:10.1001/jamaoncol.2022.0009

This cohort study analyzes histologic subtype- and stage-specific uterine cancer mortality rates by race and ethnicity.

Brief Report

Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2022;8(6):904-909. doi:10.1001/jamaoncol.2022.0212

This nonrandomized clinical trial evaluates the response rate to treatment with a combination of bevacizumab and atezolizumab in patients with advanced neuroendocrine tumors.

Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study)

Abstract Full Text
free access
JAMA Oncol. 2022;8(6):910-913. doi:10.1001/jamaoncol.2022.0238

This preliminary analysis of data from the BONSAI clinical trial examines the safety and efficacy of cabozantinib as monotherapy in patients with untreated metastatic collecting duct carcinoma.

Association of the COVID-19 Pandemic With Rates of Prostate Cancer Biopsies and Diagnoses in Black vs White US Veterans

Abstract Full Text
free access
JAMA Oncol. 2022;8(6):914-918. doi:10.1001/jamaoncol.2022.0467

This cohort study assesses the association of the COVID-19 pandemic with prostate biopsy and prostate cancer diagnosis rates among Black vs White patients in the Veterans Affairs Health Care System.

Research Letter

Ipilimumab/Nivolumab Therapy in Patients With Metastatic Pancreatic or Biliary Cancer With Homologous Recombination Deficiency Pathogenic Germline Variants

Abstract Full Text
free access
JAMA Oncol. 2022;8(6):938-940. doi:10.1001/jamaoncol.2022.0611

This case series describes ipilimumab/nivolumab therapy in patients with metastatic pancreatic or biliary cancer with homologous recombination deficiency (HRD) pathogenic germline variants (PGVs).

Long-term Immunogenicity of BNT162b2 Vaccine in Patients With Solid Tumors

Abstract Full Text
free access has active quiz
JAMA Oncol. 2022;8(6):940-941. doi:10.1001/jamaoncol.2022.1467

This cohort study examines cellular and humoral pathways at 6 months after BNT162b2 COVID-19 vaccination in patients with cancer who were receiving active antineoplastic treatment.

Special Communication

Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Systematic Review and Delphi Consensus Statement

Abstract Full Text
has active quiz
JAMA Oncol. 2022;8(6):929-937. doi:10.1001/jamaoncol.2022.0168

This systematic review evaluates baseline and prognostic factors in randomized clinical trials of resectable pancreatic cancer and, combined with expert opinion collected using the Delphi technique, recommends mandatory measures to facilitate comparison among trial outcomes.

Viewpoint

Addressing Sex Disparities in Academic Oncology: What Can We Do?

Abstract Full Text
JAMA Oncol. 2022;8(6):819-820. doi:10.1001/jamaoncol.2022.0165

This Viewpoint discusses the underrepresentation of women in academic oncology and in oncology clinical trials and proposes policy-, organization-, and individual-level changes to address the disparities.

Enabling the Sharing of Single-Dose Vials Through Risk Mitigation to Decrease Financial Toxicity

Abstract Full Text
JAMA Oncol. 2022;8(6):821-822. doi:10.1001/jamaoncol.2022.0177

This Viewpoint describes the issue of wastage related to single-use vials and offers recommendations for addressing this issue.

Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma—Challenges and Potential Solutions

Abstract Full Text
JAMA Oncol. 2022;8(6):823-824. doi:10.1001/jamaoncol.2022.0319

This Viewpoint discusses the multiple challenges that face patients and their treating oncologists when considering patients for chimeric antigen receptor T-cell therapy and assesses potential solutions.

Editorial

A Phenome-Wide Association Study and the Discovery of a New Clinical Spectrum of Hereditary Cancer Genes

Abstract Full Text
JAMA Oncol. 2022;8(6):827-828. doi:10.1001/jamaoncol.2022.0361
Invited Commentary

The ORATOR Trials Have Spoken—Where Do We Go From Here?

Abstract Full Text
JAMA Oncol. 2022;8(6):851-852. doi:10.1001/jamaoncol.2022.0461

Are We Finally Ready for the Widespread Adoption of Stereotactic Radiation in Gynecologic Cancers?

Abstract Full Text
JAMA Oncol. 2022;8(6):861-862. doi:10.1001/jamaoncol.2022.0260
Cancer Care Chronicles

A Decision Shared Is a Decision Halved

Abstract Full Text
free access
JAMA Oncol. 2022;8(6):825-826. doi:10.1001/jamaoncol.2022.0153

This essay describes the difficulty of shared decision-making about treatment placed on physicians, patients, and families during the COVID-19 pandemic.

Poetry and Oncology

Differently

Abstract Full Text
JAMA Oncol. 2022;8(6):951. doi:10.1001/jamaoncol.2022.0156
Comment & Response

Is Regional Nodal Radiotherapy Necessary for Patients With cN1 and ypN0 Breast Cancer After Neoadjuvant Chemotherapy?

Abstract Full Text
JAMA Oncol. 2022;8(6):942. doi:10.1001/jamaoncol.2022.0313

Is Regional Nodal Radiotherapy Necessary for Patients With cN1 and ypN0 Breast Cancer After Neoadjuvant Chemotherapy?—Reply

Abstract Full Text
JAMA Oncol. 2022;8(6):942-943. doi:10.1001/jamaoncol.2022.0316

Clinical Utility Assessment of Gonadotropin-Releasing Hormone Analogs Among Women Younger Than 35 Years

Abstract Full Text
JAMA Oncol. 2022;8(6):943-944. doi:10.1001/jamaoncol.2022.0488

Clinical Utility Assessment of Gonadotropin-Releasing Hormone Analogs Among Women Younger Than 35 Years—Reply

Abstract Full Text
JAMA Oncol. 2022;8(6):944. doi:10.1001/jamaoncol.2022.0491

Concerns Remain Regarding the Association of Sitting Time and Physical Activity With Cancer Survivorship

Abstract Full Text
JAMA Oncol. 2022;8(6):944-945. doi:10.1001/jamaoncol.2022.0868

Concerns Remain Regarding the Association of Sitting Time and Physical Activity With Cancer Survivorship

Abstract Full Text
JAMA Oncol. 2022;8(6):945. doi:10.1001/jamaoncol.2022.0871

Concerns Remain Regarding the Association of Sitting Time and Physical Activity With Cancer Survivorship—Reply

Abstract Full Text
JAMA Oncol. 2022;8(6):945-946. doi:10.1001/jamaoncol.2022.0874

Evidence Base on the Potential Carcinogenicity of Radiofrequency Radiation

Abstract Full Text
JAMA Oncol. 2022;8(6):946-947. doi:10.1001/jamaoncol.2022.0925

Evidence Base on the Potential Carcinogenicity of Radiofrequency Radiation

Abstract Full Text
JAMA Oncol. 2022;8(6):947-948. doi:10.1001/jamaoncol.2022.0928

Evidence Base on the Potential Carcinogenicity of Radiofrequency Radiation

Abstract Full Text
JAMA Oncol. 2022;8(6):948. doi:10.1001/jamaoncol.2022.0931

Evidence Base on the Potential Carcinogenicity of Radiofrequency Radiation—Reply

Abstract Full Text
JAMA Oncol. 2022;8(6):948-949. doi:10.1001/jamaoncol.2022.0934
Correction

Incomplete Disclosure

Abstract Full Text
free access
JAMA Oncol. 2022;8(6):949. doi:10.1001/jamaoncol.2022.1033
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2022;8(6):808. doi:10.1001/jamaoncol.2021.5501
×